Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models

Krzysztof Domka, Małgorzata Firczuk, Zuzanna Urbańska et al.|Haematologica|2024

Cited by 1